Ysios Capital Launches $110M InceptionBio Fund to Build Biotech Companies

Why It Matters

By filling the pre‑seed funding gap, the fund accelerates the translation of Spanish scientific research into commercial biotech, strengthening Europe’s life‑sciences pipeline and offering investors early exposure to high‑growth assets.

Key Takeaways

• €100M (~$108M) fund targets pre‑seed biotech creation.
• CDTI anchors fund, ensuring public‑private partnership.
• Goal: launch at least three Spanish biotech firms in 2026.
• Leaders bring exits: Sanifit sold for €375M (~$405M).
• Complements BioFund III and Telescope fund’s strong returns.

Pulse Analysis

Europe’s biotech ecosystem has long struggled with the "valley of death" that separates academic discovery from Series A financing. While many venture firms focus on later‑stage rounds, the pre‑seed phase demands patient capital, specialized expertise, and close ties to research institutions. InceptionBio’s emphasis on technology transfer directly addresses this scarcity, offering not just funding but hands‑on operational support to build founding teams and generate pre‑clinical data. This approach mirrors successful models in the United States, where university‑linked incubators have become pipelines for breakthrough therapeutics, and signals a maturation of Spain’s innovation infrastructure.

Ysios Capital leverages its deep track record—over 40 biotech exits, including the €375 million (≈$405 million) sale of Sanifit—to de‑risk early‑stage creation. The appointment of Joan Perelló, a serial entrepreneur with a chemistry background, and Arturo Urrios, who brings experience from Wellington Partners and Merck’s corporate venture arm, adds credibility and operational heft. Their combined networks enable rapid identification of high‑potential discoveries and swift formation of companies capable of attracting follow‑on capital. By targeting at least three launches in 2026, the fund sets a measurable benchmark that could catalyze a cascade of spin‑outs across Spanish universities and hospitals.

The launch also aligns with broader market trends: EU policy increasingly supports translational research, and global investors are seeking diversified exposure to life‑sciences innovation beyond traditional hubs. InceptionBio’s integration with Ysios’s later‑stage BioFund III and the publicly listed Telescope Biotech Fund creates a seamless capital continuum, allowing early ventures to graduate into larger financing rounds without leaving the Ysios ecosystem. For limited partners, this structure offers a compelling risk‑adjusted return profile—early‑stage upside paired with the safety net of established later‑stage vehicles—potentially reshaping the investment landscape for European biotech.

Deal Summary

Spain’s largest life‑sciences VC, Ysios Capital, announced the launch of InceptionBio, a $110 million fund dedicated to creating biotech companies from university spin‑outs. The fund, anchored by Spain’s Centre for Technological Development and Innovation (CDTI), aims to establish at least three new companies in 2026. The vehicle marks Ysios’s first dedicated fund for the pre‑seed stage of biotech.